ST. LOUIS, Oct. 22 /PRNewswire-FirstCall/ --
HIGHLIGHTS (all percentages are to comparable periods in 2008):
Commenting on third quarter 2009 performance, Chairman, President and CEO Jai Nagarkatti said: "We are very pleased with our improved sales performance in the third quarter of 2009 in continued challenging economic conditions. And we're particularly pleased with the $0.70 of diluted EPS delivered for the third quarter of 2009, our best quarterly performance this year. We continued our tradition of adding new and innovative products and technologies to support life science research. We were pleased to announce the expansion of our agreement with Sangamo BioSciences to use zinc finger technology in the production of therapeutic proteins and in commercial areas of transgenics. A new partnership with the Michael J. Fox Foundation to create the first Parkinson's disease model in rats has generated much excitement in the research community. The recent acquisition of ChemNavigator offers the scientific community a powerful cheminformatics platform that streamlines the design and procurement of chemical compound libraries."
Nagarkatti continued, "We've reaffirmed our sales and profit expectations for all of 2009, continuing to believe that we can achieve above-market rate organic sales growth in the low single digits and deliver diluted EPS slightly in excess of $2.70, reflecting a gain over last year's $2.65. We expect a small contribution from supplying key components to H1N1 vaccine manufacturing customers and from a slight increase in government research funding. We plan to add new sales growth and profitability enhancing activities that together with better economic conditions should improve our growth in 2010. But we expect the market recovery to be slow. With that in mind, we have identified additional initiatives to drive our core chemistry and biochemistry sales at above market growth rates. We also plan to increase our share in the faster growing biotech and analytical product areas."
Reported sales for the third quarter of 2009 were $534 million, a decline of 1.3% from the third quarter of 2008. Without reflecting an unfavorable currency impact that reduced reported sales by 3.6%, sales would have shown organic growth of 2.3%. For the nine months ended September 30, 2009, reported sales declined by 6.8% from the first nine months of 2008 while overall organic sales were largely consistent with the prior year level. Organic sales for the Company's Research business grew 1.4% and 1.9% for the third quarter and first nine months of 2009, respectively. Organic sales for SAFC increased by 4.8% for the third quarter of 2009 as sales of H1N1 vaccine adjuvants to pharma companies and shipments of industrial media and other previously booked orders drove sales for this unit to a quarterly high for 2009. Year-to-date organic sales for SAFC declined by 2.8% from the comparable prior year level. Quarterly and year-to-date comparisons and a reconciliation of reported to adjusted (organic) sales growth are on page 8.
The operating income margin in the third quarter 2009 of 22.9% of sales reflects a modest decline from levels in 2008's third quarter and 2009's first half resulting from unfavorable currency and a slight unfavorable product mix resulting from higher SAFC sales. The Company continued to take proactive steps to accelerate benefits from its global supply chain activities and to lower S,G&A costs in an effort to offset the adverse currency impact on earnings it has experienced in the first nine months of 2009.
Free cash flow (defined on page 7) for the third quarter of 2009 was $115 million, resulting in free cash provided in the first nine months of 2009 of $274 million. A reconciliation of net cash provided by operating activities to free cash flow is on page 9.
Other highlights in the third quarter from global sales growth initiatives and profit enhancement activities include:
Cash Flow and Debt: Cash flow from operations for the first nine months of 2009 was $362 million compared to $300 million for 2008. This change reflects a reduction in working capital, most notably a reduction in inventory of $39 million partially offset by a $23 million tax disbursement in 2009's second quarter due to the timing of international tax payments. Capital expenditures increased to $88 million for the nine months ended September 30, 2009 from $65 million for the same period of 2008 as the Company made investments to expand its biotech capacity in Israel and its manufacturing capacity for viral products and active pharmaceutical ingredients in the U.S. Overall free cash flow of $274 million in the first nine months of 2009 was used to repay $142 million in short-term debt and return $99 million to shareholders through share repurchases and a 12% increase in the 2009 quarterly dividend. The Company's debt to capital ratio was reduced to 25.9% at September 30, 2009 from 34.6% at December 31, 2008. The Company has not experienced any problem in placing its short-term debt in the current credit market environment.
Share Repurchase: Another 0.4 million shares were acquired in the third quarter of 2009 at an average share price of $51.65. There were 121.7 million shares outstanding at September 30, 2009. The Company has 6.7 million remaining authorized shares for purchase, but the timing and number of shares purchased, if any, depends upon market conditions and other factors.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and as key components in pharmaceutical, diagnostic and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. We are committed to accelerating our Customers' success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award winning web site at www.sigma-aldrich.com.
Non-GAAP Financial Measures: The Company uses certain non-GAAP financial measures to supplement its GAAP disclosures. The Company does not, and does not suggest investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, GAAP financial information. These non-GAAP measures may not be consistent with the presentation by similar companies in the Company's industry. Whenever the Company uses such non-GAAP measures, it provides a reconciliation of such measures to the most closely applicable GAAP measure. See the Supplemental Financial Information on pages 8 and 9 for these reconciliations.
With over 60% of sales denominated in currencies other than the U.S. dollar, management uses currency adjusted growth, and believes it is useful to investors, to judge the Company's controllable, local currency performance. Organic sales growth data presented in this release is proforma data and excludes currency impacts. While we are able to report currency impacts after the fact, we are unable to estimate changes that may occur later in 2009 to applicable exchange rates and are thus unable to reconcile the projected non-GAAP, currency adjusted internal growth rates to reported GAAP growth rates for the year 2009. Any significant changes in currency exchange rates would likely have a significant impact on our reported growth rates due to the volume of our sales denominated in foreign currencies.
Management reports both GAAP and adjusted sales and income(including EPS) and comparisons to reflect what it believes are ongoing and/or comparable operating results excluding currency impacts. Management excludes this item in judging its historical performance and in assessing its expected future performance. Management also uses free cash flow (defined on page 7), a non-GAAP measure, to judge its performance and ability to pursue opportunities that enhance shareholder value. Management believes this non-GAAP information is useful to investors as well.
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including the "Highlights-Outlook", "CEO's Statement", "2009 Outlook" and "Other Information-Cash Flow and Debt and Share Repurchase" sections contained above and other statements regarding the Company's expectations, goals, beliefs, intentions and the like regarding future sales, earnings, free cash flow, share repurchases, acquisitions and other matters. These statements are based on assumptions regarding Company operations, investments and acquisitions and conditions in the markets the Company serves. The Company believes these assumptions are reasonable and well founded. The forward looking statements in this release are subject to risks and uncertainties, including, among others, certain economic, political and technological factors. Actual results could differ materially from those stated or implied in this news release, due to, but not limited to, such factors as (1) global economic conditions, (2) changes in pricing and the competitive environment and the global demand for our products, (3) fluctuations in foreign currency exchange rates, (4) changes in research funding and the success of research and development activities, (5) dependence on uninterrupted manufacturing operations, (6) changes in the regulatory environment in which the Company operates, (7) changes in worldwide tax rates or tax benefits from domestic and international operations, including the matters described in Note 4-Uncertainty in Income Taxes-to the Consolidated Financial Statements in the Company's Form 10-Q report for the quarter ended June 30, 2009, (8) exposure to litigation, including product liability claims, (9) the ability to maintain adequate quality standards, (10) reliance on third party package delivery services, (11) failure to achieve planned cost reductions in global supply chain rationalization, (12) an unanticipated increase in interest rates, (13) failure of planned sales initiatives in our Research and SAFC businesses, (14) other changes in the business environment in which the Company operates, and (15) the outcome of the matters described in Note 13-Contingent Liabilities and Commitments-to the Consolidated Financial Statements in the Company's Form 10-Q report for the quarter ended June 30, 2009. A further discussion of the Company's risk factors can be found in Item 1A of the Company's Form 10-K report for the year ended December 31, 2008. The Company does not undertake any obligation to update these forward-looking statements.
Subscribe to our Free Newsletters!
Craniosynostosis is a condition where the bones of the skull are fused together prematurely ...
Episiotomy is a surgical incision made in the perineum between the vaginal orifice and the anus ...
Stickler syndrome is a rare genetic disorder which causes multisystem disorders predominantly ...View All